Page last updated: 2024-11-05

lysidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lysidine: structure in first source; do not confuse with the imidazole-derivative known as lysidine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lysidine : Cytidine in which the 2-keto group on the cytosine ring is substituted by an epsilon-Llysyl residue. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10798
CHEMBL ID3935635
MeSH IDM0265879

Synonyms (45)

Synonym
4,5-dihydro-2-methyl-1h-imidazol [iupac]
5-23-03-00385 (beilstein handbook reference)
4,5-dihydro-2-methyl-1h-imidazol
unii-987f50e3pe
2-methyl-20imidazolin
987f50e3pe ,
4-amino-2-(n(6)-lysino)-1-ribofuranosylpyrimidine
lysidine
1h-imidazole, 4,5-dihydro-2-methyl-
ai3-16866
2-methylimidazoline
einecs 208-596-6
2-imidazoline, 2-methyl-
methylglyoxalidine
brn 0104225
4,5-dihydro-2-methyl-1h-imidazole
2-methyl-2-imidazoline, 95%
inchi=1/c4h8n2/c1-4-5-2-3-6-4/h2-3h2,1h3,(h,5,6)
vwsllsxlurjcdf-uhfffaoysa-
2-methyl-4,5-dihydro-1h-imidazole
AKOS000271199
M0579
534-26-9
2-methyl-2-imidazoline
A829579
F1918-0077
FT-0612921
S11926
2-methyl-4,5-dihydroimidazole
2-methyl-.delta.2-imidazoline
lysidine [mi]
2-methyl-4,5-dihydro-1h imidazole
2-methyl4,5-dihydroimidazole
methyl glyoxaidine
4-methyl-2-imidazoline
2-methyl-4,5-dihydro-1h-imidazole #
DTXSID2060204
lysidin
CHEMBL3935635
mfcd00051490
AS-61384
Q423614
CS-0282476
EN300-25444
Z204020260

Research Excerpts

Overview

Lysidine is an essential modification that determines both the codon and amino acid specificities of tRNA(Ile)

ExcerptReferenceRelevance
"Lysidine is an essential modification that determines both the codon and amino acid specificities of tRNA(Ile)."( Discovery and characterization of tRNAIle lysidine synthetase (TilS).
Miyauchi, K; Suzuki, T, 2010
)
1.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPĪ± Checkpoint.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.26)18.7374
1990's1 (5.26)18.2507
2000's7 (36.84)29.6817
2010's9 (47.37)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.10 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.31 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (26.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (73.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]